AbelZeta Pharma 
Welcome,         Profile    Billing    Logout  
 15 Products   6 Diseases   15 Products   29 Trials   345 News 


12345»
  • ||||||||||  prizloncabtagene autoleucel (JNJ-4496) / J&J
    Trial completion:  A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects (clinicaltrials.gov) -  May 23, 2025   
    P1,  N=25, Completed, 
    Trial completion date: Oct 2022 --> Jun 2024 | Recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  prizloncabtagene autoleucel (JNJ-4496) / J&J
    P1 data, Journal:  A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. (Pubmed Central) -  Apr 3, 2025   
    P1
    Patients with CD19 and/or CD20-positive R/R B-NHL received a 3-day lymphodepletion (cyclophosphamide: 300 mg/m2 per day; fludarabine: 30 mg/m2 per day) followed by an IV dose of prizlon-cel...Prizlon-cel showed a favorable safety profile and a high and durable response in patients with r/r B-NHL, suggesting a promising treatment option for patients with r/r B-NHL. (ClinicalTrials.gov number: NCT04317885, NCT04655677, NCT04696432, NCT04693676).
  • ||||||||||  prizloncabtagene autoleucel (JNJ-4496) / J&J
    Phase classification, Enrollment change, Trial completion date, Trial primary completion date:  ELEVATION: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (clinicaltrials.gov) -  Nov 6, 2024   
    P1/2,  N=112, Recruiting, 
    This trial was registered with ClinicalTrials.gov, NCT04316624 and NCT04036019. Phase classification: P1b/2 --> P1/2 | N=72 --> 112 | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: Mar 2027 --> Oct 2025
  • ||||||||||  XB.2.2 / AbelZeta Pharma
    Journal, IO biomarker:  LIN28 upregulation in primary human T cells impaired CAR T antitumoral activity. (Pubmed Central) -  Oct 31, 2024   
    LIN28 overexpression maintained human T cell phenotype markers and functionality but impaired the antitumoral cytotoxicity of NKG2D-CAR T cells both in vitro and in vivo. These findings highlight the intricate relationship between LIN28/let-7 axis and human T cell functionality, including in CAR T cell therapy.
  • ||||||||||  Epidaza (chidamide) / Chipscreen, AiRuiKa (camrelizumab) / HLB Bio Group, CART-30 / AbelZeta Pharma
    Biomarker, Journal, Tumor microenvironment:  Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma. (Pubmed Central) -  Aug 2, 2024   
    P2
    In this study, we evaluated the efficacy and safety of a triplet regimen consisting of the histone deacetylase inhibitor chidamide, decitabine and anti-PD-1 camrelizumab (CDP) in 52 patients with relapsed/refractory cHL who had previously received DP therapy (NCT04233294)...The classical CD30+ HRS-like cells interacted with the abundant immunosuppressive IL21+CD4+ T helper cells, forming a positive feedback loop that supported their survival...CDP treatment promoted the activation of diverse tumor-reactive CD8+ T cells and suppressed the proliferation of IL21+CD4+ T cells by inhibiting STAT1/3 signaling, thereby alleviating their immunosuppressive effects. These findings provide insights into the cHL microenvironment that contributes to anti-PD-1 resistance and highlight the therapeutic effectiveness of dual epi-immunotherapy in overcoming immunotherapy resistance.
  • ||||||||||  human adipose derived mesenchymal progenitor cell therapy / Cellular Biomedicine, ReJoin (human adipose-derived mesenchymal progenitor cells) / Cellular Biomedicine, AlloJoin (allogeneic human adipose-derived mesenchymal stem cell therapy) / Cellular Biomedicine
    Trial completion date, Trial suspension, Trial primary completion date, Gram negative:  A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection (clinicaltrials.gov) -  Jul 22, 2024   
    P1/2,  N=60, Suspended, 
    These findings provide insights into the cHL microenvironment that contributes to anti-PD-1 resistance and highlight the therapeutic effectiveness of dual epi-immunotherapy in overcoming immunotherapy resistance. Trial completion date: Jul 2023 --> Mar 2025 | Recruiting --> Suspended | Trial primary completion date: May 2023 --> Dec 2024
  • ||||||||||  MSCs-Exos / AbelZeta Pharma
    Trial completion, Enrollment change:  A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS (clinicaltrials.gov) -  Jul 22, 2024   
    P1/2,  N=18, Completed, 
    Trial completion date: Jul 2023 --> Mar 2025 | Recruiting --> Suspended | Trial primary completion date: May 2023 --> Dec 2024 Recruiting --> Completed | N=169 --> 18
  • ||||||||||  C-TIL051 / AbelZeta Pharma
    Enrollment open, Metastases:  C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) -  Mar 1, 2024   
    P1,  N=20, Recruiting, 
    Trial completion date: Oct 2027 --> Oct 2028 Not yet recruiting --> Recruiting
  • ||||||||||  C-TIL051 / AbelZeta Pharma
    Trial completion date, Trial primary completion date, Metastases:  C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) -  Dec 31, 2023   
    P1,  N=20, Not yet recruiting, 
  • ||||||||||  JNJ-9530 / J&J
    Enrollment open, Phase classification, Enrollment change, Trial completion date, Trial primary completion date:  A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (clinicaltrials.gov) -  Nov 18, 2023   
    P1,  N=92, Recruiting, 
    Trial completion date: Apr 2027 --> Oct 2027 Not yet recruiting --> Recruiting | Phase classification: P1b --> P1 | N=52 --> 92 | Trial completion date: Nov 2026 --> May 2027 | Trial primary completion date: May 2026 --> Apr 2027
  • ||||||||||  prizloncabtagene autoleucel (JNJ-4496) / J&J
    Enrollment change, Trial completion date:  A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Nov 18, 2023   
    P1,  N=92, Recruiting, 
    Not yet recruiting --> Recruiting | Phase classification: P1b --> P1 | N=52 --> 92 | Trial completion date: Nov 2026 --> May 2027 | Trial primary completion date: May 2026 --> Apr 2027 N=52 --> 92 | Trial completion date: Oct 2027 --> Apr 2027
  • ||||||||||  C-TIL051 / AbelZeta Pharma
    Trial initiation date, Metastases:  C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) -  Sep 15, 2023   
    P1,  N=20, Not yet recruiting, 
    Intranasal administration of ahaMSCs-Exos was safe and well tolerated, and a dose of at least 4 Initiation date: Mar 2023 --> Dec 2023
  • ||||||||||  prizloncabtagene autoleucel (JNJ-4496) / J&J
    Enrollment change, Trial completion date, Trial primary completion date:  A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Sep 13, 2023   
    P1,  N=52, Recruiting, 
    Initiation date: Mar 2023 --> Dec 2023 N=15 --> 52 | Trial completion date: Jul 2038 --> Oct 2027 | Trial primary completion date: May 2025 --> May 2026
  • ||||||||||  JNJ-9530 / J&J
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy (clinicaltrials.gov) -  Jul 20, 2023   
    P1,  N=7, Completed, 
    Active, not recruiting --> Completed Unknown status --> Completed | N=10 --> 7 | Trial completion date: Dec 2021 --> Feb 2023 | Trial primary completion date: Aug 2021 --> Feb 2023
  • ||||||||||  JNJ-9530 / J&J
    Trial completion:  A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy (clinicaltrials.gov) -  Jul 20, 2023   
    P1,  N=14, Completed, 
    Unknown status --> Completed | N=10 --> 7 | Trial completion date: Dec 2021 --> Feb 2023 | Trial primary completion date: Aug 2021 --> Feb 2023 Unknown status --> Completed
  • ||||||||||  JNJ-9530 / J&J
    Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date:  A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (clinicaltrials.gov) -  Jul 12, 2023   
    P1,  N=52, Not yet recruiting, 
    Unknown status --> Completed N=15 --> 52 | Trial completion date: Oct 2025 --> May 2026 | Initiation date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jul 2025 --> May 2026
  • ||||||||||  prizloncabtagene autoleucel (JNJ-4496) / J&J
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma (clinicaltrials.gov) -  May 31, 2023   
    P1,  N=7, Active, not recruiting, 
    N=15 --> 52 | Trial completion date: Oct 2025 --> May 2026 | Initiation date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jul 2025 --> May 2026 Recruiting --> Active, not recruiting | N=10 --> 7 | Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Jul 2023
  • ||||||||||  prizloncabtagene autoleucel (JNJ-4496) / J&J
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects (clinicaltrials.gov) -  May 26, 2023   
    P1,  N=25, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=10 --> 7 | Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Jul 2023 Recruiting --> Active, not recruiting | Trial completion date: Aug 2021 --> Dec 2023 | Trial primary completion date: Aug 2021 --> Jun 2023